NCT02228460View on ClinicalTrials.gov

Evaluate the Safety, Pharmacodynamics, Pharmacokinetics, and Exploratory Efficacy of GZ/SAR402671 in Treatment-naïve Adult Male Patients With Fabry Disease

PHASE2CompletedINTERVENTIONAL
Enrollment

11

Participants

Timeline

Start Date

November 30, 2014

Primary Completion Date

September 30, 2016

Study Completion Date

September 30, 2016

Conditions
Fabry Disease
Interventions
DRUG

GZ/SAR402671

Pharmaceutical form: Capsule; Route of administration: Oral

Trial Locations (8)

22030

Investigational Site Number 840001, Fairfax

30322

Investigational Site Number 840002, Atlanta

45229

Investigational Site Number 840003, Cincinnati

92380

Investigational Site Number 250001, Garches

125167

Investigational Site Number 643002, Moscow

04-730

Investigational Site Number 616001, Warsaw

B15 2TH

Investigational Site Number 826003, Birmingham

CB2 OQQ

Investigational Site Number 826002, Cambridge

All Listed Sponsors
lead

Genzyme, a Sanofi Company

INDUSTRY

NCT02228460 - Evaluate the Safety, Pharmacodynamics, Pharmacokinetics, and Exploratory Efficacy of GZ/SAR402671 in Treatment-naïve Adult Male Patients With Fabry Disease | Biotech Hunter | Biotech Hunter